Document is current

Article History

Received: 3 June 2025

Accepted: 11 August 2025

First Online: 26 August 2025

Declarations

:

: The study was not funded.

: TK has received honoraria for lectures/advisory boards and research support from AstraZeneca, Boehringer Ingelheim, Pharmaserve Lilly, Sanofi, ELPEN, Menarini, and Novo Nordisk. DV has received honoraria for lectures/advisory boards from AstraZeneca, Boehringer, and Elpen. CV has received research grants and honoraria from AstraZeneca and Boehringer Ingelheim. KK has received honoraria for lectures/advisory boards and research support from AstraZeneca, Boehringer Ingelheim, Pharmaserve Lilly, Sanofi-Aventis, ELPEN, MSD, and Novo Nordisk. ENL has participated in educational, research, and advisory activities sponsored by AstraZeneca, MSD, Lilly, Bayer, Amgen, Sanofi, Boehringer Ingelheim, Novartis, Novo Nordisk, and Servier. EH has received honoraria for lectures/advisory boards and research support from Eli Lilly, Bristol/AstraZeneca, NovoNordisk, Menarini, WinMedica, Boehringer Ingelheim, Sanofi, Novartis, and ELPEN. EK and IS have no conflicts of interest.

: TK reviewed the literature and wrote the first version of the manuscript. DV, CV, EK, KK, ENL, IS, and EH reviewed the literature and edited the manuscript. All authors have read and approved the final version of the manuscript.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.